SCHEMBL338773

SCHEMBL338773

O=C(O)Cn1cnc2ncncc21

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 4/20 0.52
HDAC1 Q13547 1/20 0.52
LTA4H P09960 1/20 0.45
CSNK2A2 P19784 2/20 0.41
CSNK2A1 P68400 2/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTGS2 P35354 2/20 0.40
LMNA P02545 1/20 0.37
ADORA2B P29275 1/20 0.37
KMT2A Q03164 1/20 0.33
FDPS P14324 1/20 0.33
EGLN3 Q9H6Z9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48336 0.75 ADORA2A (0.47) HDAC6HDAC1LTA4HALDH1A1KDM4E
SCHEMBL3487811 0.75 HDAC6 (0.44) HDAC6HDAC1LTA4HADORA2B
SCHEMBL1692456 0.73 FDPS (0.56) HDAC6HDAC1LTA4HCSNK2A2CSNK2A1
SCHEMBL3671304 0.72 LTA4H (0.50) HDAC6HDAC1LTA4HTDP1
SCHEMBL11066170 0.72 ADORA2A (0.50) HDAC6HDAC1LTA4HKDM4ELMNA
SCHEMBL15156969 0.72 LTA4H (0.47) HDAC6LTA4HCSNK2A2CSNK2A1ALDH1A1
SCHEMBL325140 0.72 HDAC1 (0.61) HDAC6HDAC1LTA4HALDH1A1LMNA
SCHEMBL4262821 0.72 FDPS (0.62) HDAC6HDAC1LTA4HFDPS
SCHEMBL13044929 0.71 HDAC6 (0.47) HDAC6HDAC1LTA4HALDH1A1LMNA
SCHEMBL5635371 0.71 LTA4H (0.49) HDAC6HDAC1LTA4HCSNK2A2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
US-9326934-B2 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG 2016-05-03 US disclosed
EP-2181704-B1 Drug delivery from rapid gelling polymer composition ANGIOTECH INT AG (CH) 2015-05-06 EP disclosed
US-20130289235-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS, INC. (CA) 2013-10-31 US disclosed
US-8486437-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-07-16 US disclosed
US-8481073-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-07-09 US disclosed
US-8460708-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-06-11 US disclosed
US-20130012683-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-01-10 US disclosed
US-8303973-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2012-11-06 US disclosed
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG 2012-10-04 US disclosed
WO-2005051444-A2 SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051316-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051871-A2 IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005046516-A2 MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-05-26 WO disclosed
WO-2005018683-A2 ANASTOMOTIC CONNECTOR DEVICES ANGIOTECH INTERNATIONAL AG (CH) 2005-03-03 WO disclosed
US-20040260318-A1 Anastomotic connector devices ANGIOTECH INTERNATIONAL AG (CH) 2004-12-23 US disclosed
US-20040225077-A1 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG (CH) 2004-11-11 US disclosed
US-20040219214-A1 Tissue reactive compounds and compositions and uses thereof ANGIOTECH INTERNATIONAL AG (CH) 2004-11-04 US disclosed
WO-2004060346-A2 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG (CH) 2004-07-22 WO disclosed
WO-2004060405-A2 TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF ANGIOTECH INTERNATIONAL AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040219214-A1 Tissue reactive compounds and compositions and uses thereof CD44, SELP, EPCAM HDAC6 1578/4885HDAC1 3575/4885LTA4H 422/4885
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION PGF, VCAM1, COL14A1 HDAC6 1584/4885HDAC1 1665/4885LTA4H 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.